A Study to Evaluate the Pharmacokinetic Exposure of 2 Formulations of Apremilast in Healthy Adults
Status:
Completed
Trial end date:
2016-11-22
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the relative bioavailability of apremilast
once-daily formulation relative to a twice daily formulation when administered as multiple
doses (Part 1), and when administered as a single dose under fasting and fed conditions (Part
2). Information on safety and tolerability will also be obtained.